Status:
COMPLETED
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI
Lead Sponsor:
Max Planck Institute for Human Cognitive and Brain Sciences
Collaborating Sponsors:
Leipzig University Medical Center
Hannover Medical School
Conditions:
Gilles de la Tourette Syndrome
Tourette Syndrome
Eligibility:
All Genders
18-50 years
Brief Summary
Gilles de la Tourette syndrome (GTS; also known as Tourette syndrome) is a congenital neuropsychiatric disorder. Characteristic symptoms are so-called tics-rapid, repetitive movements (motor tics) or ...
Detailed Description
State of the Art Gilles de la Tourette Syndrome (GTS) is characterized by the presence of motor and vocal tics, which have been defined as rapid, habitual, burst-like movements or utterances that typ...
Eligibility Criteria
Inclusion
- GTS Group:
- GTS according to DSM-IV-TR criteria
- mild or moderate tics
- drug-free for a minimum of 4 weeks prior to the exam
Exclusion
- severe tics of the head and/or face
- psychiatric medication within 4 weeks prior to the exam
- consumption of alcohol during 24 hours prior to the exam
- consumption of cannabis during 24 hours prior to the exam • pregnancy
- general contra-indications for MRI exams
- Control Group:
- Inclusion Criteria:
- • no known neurological or psychiatric disease
- Exclusion criteria:
- psychiatric medication within 4 weeks prior to the exam
- consumption of alcohol during 24 hours prior to the exam
- consumption of cannabis during 24 hours prior to the exam • pregnancy
- general contra-indications for MRI exams
Key Trial Info
Start Date :
May 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 4 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05232955
Start Date
May 4 2022
End Date
July 4 2023
Last Update
April 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Max Planck Institute for Human Cognitive and Brain Sciences
Leipzig, Germany, 04103